Announcement on the progress of entrusted financial management
Release time:
2020-08-05
证券简称:尖峰集团 证券代码:600668 编号:临2019-020
债券简称:13尖峰02 债券代码:122344
浙江尖峰集团股份有限公司
关于委托理财进展情况的公告
本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。
重要内容提示:
l 委托理财受托方:广发银行股份有限公司金华分行
l 委托理财金额:10000万元人民币
l 委托理财投资类型:保本浮动收益型结构性存款
l 委托理财期限:2019年5月9日—2019年11月11日
一、本次委托理财概述
(一)本次委托理财的基本情况
公司于2019年5月9日与广发银行股份有限公司金华分行(以下简称“广发银行金华分行”)签署《广发银行“薪加薪16号”人民币结构性存款合同》,公司出资10,000万元人民币购买广发银行金华分行发售的人民币结构性存款XJXCKJ7586号产品,产品期限186天,预期年化收益率4.25%,本产品为保本浮动收益型产品。
公司本次投资委托理财产品的资金为运营中暂时闲置的自有资金,进行短期委托理财,能提高资金使用效率。本次委托理财不构成关联交易。
(二)公司内部需履行的审批程序。
2019年4月26日,公司召开的第十届董事会第10次会议审议通过了《关于授权公司董事长决定委托理财的议案》。授权公司董事长行使不超过人民币5亿元的委托理财的决策权,在该额度内资金可以滚动使用,但任一时点存续的委托理财余额合计不得超过5亿元,每笔委托理财的期限均不得超过12个月。详见本公司在2019年4月30日在上海证券交易所网站披露的《关于授权公司董事长利用自有资金进行委托理财的公告》(临2019-012)。
公司本次购买广发银行金华分行发售的单位结构性存款XJXCKJ7586理财产品,在公司第十届董事会第10次会议授权董事长决策范围之内。
二、本次委托理财协议主体的基本情况
(一)交易对方名称:广发银行股份有限公司金华分行,公司类型:股份有限公司分公司(国有控股),营业场所:浙江省金华市婺城区八一南街999号赞佳大厦主楼1-4层、裙楼2-3层及4层局部,负责人:李振岳,经营范围:经营中国银行业监督管理委员会依照有关法律、行政法规和其他规定批准的业务,经营范围以批准文件所列的为准。(依法须经批准的项目,经相关部门批准后方可开展经营活动)
(二)广发银行股份有限公司金华分行与本公司之间在产权、业务、资产、债权债务、人员等方面均不存在关联关系。
三、 本次委托理财合同的主要内容
(一)基本说明
公司本次购买理财产品的资金来源为公司自有资金,委托理财期限为 2019年5月9日至2019年11月11日,该产品为保本浮动收益型结构性存款产品,预期年化收益率为2.6%或4.25%,无需提供履约担保。银行和投资者应各自承担其在本合同项下应交纳的税费。本产品收益的计算中已包含(计入)银行的运营管理成本(如账户监管、资金运作管理、交易手续费等),公司无需支付或承担本产品下的其他费用或收费。
(二)产品说明
1、投资方向及受益权比例
本结构性存款所募集的资金本金部分纳入广发银行金华分行资金统一运作管理,投资于货币市场工具(包括但不限于银行存款、拆借、回购等)的比例区间为20%-100%、债券(包括但不限于国债、央票、金融债、短期融资券、企业债、中期票据、公司债)等金融资产的比例区间为0%-80%,收益部分投资于与美元兑港币的汇率水平挂钩的金融衍生产品,投资者的结构性存款收益取决于美元兑港币的汇率在观察期间内的表现。
2、收益计算
结构性存款收益率与美元兑港币的最终汇率水平挂钩。美元兑港币的最终汇率是指2019年05月20日路透页面香港时间上午11:30“ HKDFIX”公布的美元兑港币汇率。如果届时约定的数据提供商路透资讯(Reuters)页面不能给出适用的价格水平,或者用于价格水平确定的版面或时间发生变化,广发银行将本着公平、公正、公允的原则,选择市场认可的合理的价格水平进行计算。
汇率区间为(7.0000, 9.0000),即汇率区间下限为7.0000,汇率区间上限为9.0000。
结构性存款收益说明:
(1)如果美元兑港币的最终汇率始终位于汇率区间内(不含边界点),则到期时结构性存款收益率为4.25%(年化收益率);
(2)如果美元兑港币的最终汇率始终位于汇率区间外(含边界点),则到期时结构性存款收益率为2.6%(年化收益率)。
结构性存款收益情景模拟:
|
|
观察日美元兑港币的最终汇率P |
年化收益率 |
|
情景一 |
P≥9.0000 或 P≤7.0000 |
2.6% |
|
情景二 |
7.0000<P<9.0000 |
4.25% |
投资者获得的结构性存款收益=结构性存款本金×到期年化收益率×实际结构性存款天数÷365,精确到小数点后2位。
3、提前终止:
本结构性存款存续期内,结构性存款投资者无提前终止权利。
4、提前赎回:
本结构性存款投资期间不设提前赎回,结构性存款投资者无提前赎回该结构性存款的权利。
5、本金及收益兑付:
本结构性存款成立且投资者持有该结构性存款直至到期日,则广发银行在结构性存款到期日向投资者偿付全部人民币本金,并按照规定向投资者支付结构性存款收益。
6、产品特点
(1)本金安全,提供博取更高收益的机会:在持有到期的情况下产品可以保证投资者本金不受损失。
(2)指标客观,结构简单:本结构性存款的收益与美元兑港币的汇率水平挂钩。
(三)敏感性分析
公司本次以自有资金10,000万元购买的广发银行金华分行结构性存款XJXCKJ7586号产品期限较短,不会对公司生产经营状况造成影响。在该投资期限内减少公司现金流净额10,000万元,到期后预期为公司产生收益216.58万元。
(四)风险控制分析
本产品为保本浮动收益型产品,银行确保公司本金安全,符合公司维护全体股东和公司利益的原则。公司始终将委托理财产品风险防控工作放在首位,严格按照内控制度有关规定,投资委托理财产品均为期限短、安全性高、流动性好的低风险银行理财产品。公司对购买的理财产品严格把关,谨慎决策。
(五)独立董事意见
公司召开的第十届董事会第10次会议审议通过了《关于授权公司董事长利用自有资金进行委托理财的议案》,独立董事发表了独立意见,认为:公司委托理财是在确保公司日常运营和资金安全的前提下实施的,不影响公司日常资金周转,不影响公司经营业务的正常开展。通过进行适度的低风险的理财产品投资业务,可以提高资金使用效率,能获得一定的投资效益,为公司股东谋取更多的投资回报。未发现有损害公司及中小股东权益的情形。同意授权董事长利用自有资金进行委托理财。
四、公司累计进行的委托理财情况
公司曾于2019年1月31日,在《上海证券报》、《中国证券报》及上海证券交易所网站上披露了《关于委托理财进展情况的公告》。截至本公告日,公司已经收回了全部到期的委托理财。
前次进展公告后,截至本公告日,公司累计进行委托理财的金额为4亿元。详见下表:
|
序号 |
受托人 |
理财产品类型 |
金额
(万元) |
起始日 |
到期日 |
截止公告日已收回本金金额(万元) |
截止公告日获得收益(万元) |
|
1 |
交通银行金华分行 |
蕴通财富定期型结构性存款 |
3,000.00 |
2019/2/1 |
2019/6/6 |
/ |
More information Pharmaceutical Company Established New Drug R & D Promotion Committee Recently, the new drug research and development promotion committee of Jianfeng pharmaceutical company was formally established, which will be responsible for promoting the new drug research and development progress of pharmaceutical companies and subordinate enterprises, and coordinating the new drug research and development work of various departments and subordinate enterprises. The New Drug Promotion Committee is headed by Huang Jinlong, deputy general manager of the group and general manager of the pharmaceutical company, and Jiang Hong, deputy general manager of the pharmaceutical company, is headed by Pang Xiong, Shi Cunyuan, Xu Lizhen, Yu Jingjing, Zheng Kunwu, Feng Lixiang, Kang Litao, Li Qian, Wu Chonggui, Zhai Tsunami, Huang Fang and Tong Xiaojun. The committee has an office, and Shi Cunyuan is also the director of the office, responsible for the supervision, communication, and coordination of the company's new drug research and development projects. The main responsibilities of the new drug promotion committee include: organizing the establishment and improvement of the R & D project management system and relevant regulations of the pharmaceutical company; organizing the formulation of the development plan of the new drug R & D project of the pharmaceutical company and supervising the implementation; making decisions on project initiation and participating in project evaluation; supervising the management of new drug R & D of the pharmaceutical company and providing guidance; Responsible for the process management of new drug R & D projects and the promotion and coordination of new drug R & D; carry out the assessment of new drug research and development projects; issue the responsibility system assessment and task statement of new drug research and development projects; be responsible for solving major technical problems in the process of new drug research and development; be responsible for the research and improvement of the management mode of research and development projects of pharmaceutical companies; be responsible for the future trend analysis of new drug research and development projects; review the major scientific research achievements of pharmaceutical companies and put forward reward suggestions. Huang Jinlong said that the research and development of new drugs is an important foundation for the healthy development of the pharmaceutical industry and is a systematic project. Jianfeng Pharmaceutical has always attached great importance to the research and development of new drugs, but there is still a certain gap between the progress of research and development and the development process of the enterprise, and the lack of coordination in the research and development process also affects the progress and quality of new drug research and development to a certain extent. The purpose of the establishment of the New Drug Research and Development Promotion Committee is to solve the progress of new drug research and development, to find and solve problems in time, to implement more targeted, and to effectively integrate enterprise resources, improve the speed and quality of new drug research and development, and make good product reserves for the healthy development of pharmaceutical companies. (Reporter Ni Yingzhen) 2020 09-11 Jianfeng Pharmaceutical ranks among the top 100 Chinese pharmaceutical industries in 2019 On August 25, the "2019 Top 100 Series List of China's Pharmaceutical Industry" was released in Kunming. Zhejiang Jianfeng Pharmaceutical Company was shortlisted as one of the top 100 enterprises in China's pharmaceutical industry. The product Berunning (Olopatadine Hydrochloride Eye Drops) was selected as the "Most Growing Product Brand" of China's pharmaceutical industry ". The "Top 100 Pharmaceutical Industry Series List" was evaluated and released by Guangzhou Punctuation Pharmaceutical Information Co., Ltd., a subsidiary of the Southern Institute of Pharmaceutical Economics of the State Drug Administration, and is known as the "Oscar in Chinese Pharmaceutical Industry. Southern Institute is the earliest institution in China that specializes in pharmaceutical industry policy and market economy research, pharmaceutical market research, pharmaceutical economic data analysis and research, and pharmaceutical professional media publishing. It is in the field of market information value-added services and media communication and marketing services in China's pharmaceutical and health industry., The field of professional quality improvement has extremely extensive influence. The "Top 100 Pharmaceutical Industry" is comprehensively evaluated by the company's annual pharmaceutical industry sales revenue, total profit and R & D investment results. On the same day, the "most growing product brand" of Chinese medicine selected by the Southern Institute's media "Pharmaceutical Economic News" was released simultaneously. Spike Pharmaceuticals product Beirunning (Olopatadine Hydrochloride Eye Drops) was selected. (Xu Yuting) 2020 09-01 Company Disclosure 2020 Semi-Annual Report On August 28, the Group held the 16th meeting of the 10th Board of Directors of the Company by means of communication, and considered and adopted the "2020 Semi-Annual Report of Jianfeng Group" and the "Proposal on Changes in the Company's Accounting Policy". On August 29, the Company's 2020 semi-annual report was publicly disclosed on the Shanghai Stock Exchange and the Shanghai Securities News and China Securities News. In the first half of the year, the Group focused on the general policy of "grasping projects, making up for shortcomings, improving quality and efficiency, and constantly improving the core competitive advantage", and on the basis of doing a good job in epidemic prevention and control, the Group seized the resumption of work and production, accelerated project construction, and enhanced the core competitiveness of enterprises. In the first half of 2020, the company achieved total operating income of 1.44 billion yuan, net profit attributable to shareholders of 0.368 billion yuan, net profit per share of 1.07 yuan. As of the end of June 2020, the Company's total assets were $5.892 billion, net assets were $4.068 billion, and net assets per share were $11.82. From February to April, affected by the epidemic, the national project construction progress slowed down, cement market demand decreased; after May, the epidemic was effectively controlled, infrastructure investment continued to recover, the real estate industry continued to pick up, cement sales steadily rebounded. During the outbreak, Daye Peak completed the technical transformation projects such as the cold machine, cement mill, into the desulfurization tower anti-corrosion transformation, to ensure the efficient operation of the production equipment after the resumption of work. Yunnan peak rotary kiln production, cement production and other major technical and economic indicators of steady rise; comply with market trends, timely adjustment of marketing policies. Guizhou Jianfeng has promoted the project infrastructure construction, equipment installation and commissioning, raw material bidding and other work in an orderly manner, and through preliminary publicity to enhance the popularity of the Jianfeng brand in the local area, and make a series of preparations for the transformation from project construction to production and operation. In the first half of 2020, the reform of China's medical and health system continued to deepen, and new policies were introduced intensively. Peak Pharmaceuticals and its subsidiaries in the epidemic prevention work at the same time in the first time to achieve the resumption of production, and actively organize donations to support the fight against the epidemic, was named the annual "war epidemic star" the most socially responsible pharmaceutical enterprises. In the first half of the year, Jianfeng Pharmaceutical continued to increase the introduction and development of varieties, and JFAN-1001 applied for clinical application of new anti-tumor drugs. At present, it has obtained the notice of approval for clinical trials. Optimize the production process of API workshop and further shorten the production cycle of raw materials. Continue to improve product sales policies and strengthen market channel control. Shanghai North Carolina further straightened out the internal management structure, production and marketing convergence more smoothly, continue to promote the construction of Anhui North Carolina and Anhui Zhongwang Phase II technical transformation project, promote the peak pharmaceutical raw materials, preparations integration of industrial upgrading strategy. Other business segments of the company actively responded to the challenge of the new crown epidemic and carried out production and operation activities in a standardized and orderly manner. Tianjin natural products company vigorously explore the international and domestic markets, sales revenue to achieve steady growth. Peak Health focuses on the basic idea of "sales orientation, burden reduction and efficiency improvement, fine-grained savings, cost reduction and efficiency enhancement" to effectively improve the operational efficiency of enterprises. Jianfeng International Trade has actively developed new storage business varieties and achieved practical results, and has become the first enterprise in Jinhua to formally obtain the qualification of "network freight. Peak cable seizes the special needs of communication cables such as subways, vigorously promotes large logarithmic cables for subways, and strives to achieve the long tail effect. On the same day, the company also held the 10th meeting of the Ninth Board of Supervisors and reviewed and approved relevant reports. (residual fruit) 2020 09-01 The company organizes new employee induction training From August 12 to 14, in order to strengthen the training of talents in the group and improve the comprehensive quality of new employees, Jiang Xiaomeng, secretary of the party committee and chairman of the group company, Yu Jianhong, general manager, and other leaders and heads of relevant enterprises and departments conducted a three-day induction training for new employees. New employees from foreign enterprises such as Guizhou Huangping Peak, Daye Peak and Shanghai North Carolina participated simultaneously through online methods. In the course of corporate culture, General Manager Yu Jianhong started from the history of the development and struggle of the peak, divided into five stages: hard work, determined reform, diversified development, strategic adjustment, and strategic development, and introduced in detail the development process of the group company and the current industrial layout., The results achieved; from the aspects of enterprise spirit, vision, development philosophy, values, business philosophy, etc, this paper introduces the peak corporate culture rooted in 62 years of history and inherited in the blood; from the perspective of an enterprise manager and old employees, he speaks a lot of truth to the new employees and puts forward a lot of hopes and suggestions. Chairman Jiang Xiaomeng took "How New Employees Achieve Win-Win with Enterprises" as the topic, and proposed that the key to the success of an enterprise lies in how to select, retain, educate and employ people. Peak and employees complement each other. Peak can achieve today's achievements and the struggle of generations of peak people are inseparable. He also taught new employees the basic concepts that need to be understood, the basic qualities that need to be possessed and the sense of hardship in entering the new environment through 16 key words, and combined with his own experience and quoting from others, he analyzed the core elements of success, the signs of a successful career, the personal qualities that need to be possessed for success, and the importance of establishing a personal knowledge management system, it expresses the ardent hope of new employees to adjust their mentality, keep learning, clear goals, clear dreams, cultivate win-win thinking, and grow up together with the peak. The heads of the human resources department of the group company, the safety management office of the group company, and the comprehensive department of the pharmaceutical company also taught the new employees the corporate rules and regulations and the "Employee Handbook", safety knowledge and professional ethics. The new employees also visited the group exhibition hall and had a deeper understanding of the development history and enterprise achievements of the peak. After the training, the human resources department also organized an examination to test the training effect. (Reporter Chen Shengmu) 2020 08-21 According to this newspaper, through the interconnection monitoring of the transportation department in Zhejiang province, the network freight platform of peak international trading company passed the online service capability audit, interface access audit, eight capability identification and other audit procedures, and successfully obtained the road transportation business license with the qualification of "network freight" on July 2. It is understood that Jianfeng International Trade is currently the first enterprise in Jinhua and Quzhou to obtain this qualification. 2020 08-05 News from our newspaper On July 21, Xi Jinping, General Secretary of the Central Committee of the Communist Party of China, President of the State, and Chairman of the Central Military Commission hosted a symposium for entrepreneurs in Beijing and delivered an important speech. Over the past few days, the General Secretary's speech has aroused strong repercussions in all walks of life. On July 23, Jiang Xiaomeng, chairman of the group company, said in an interview with Jinhua TV that the general secretary's speech was calm and inspiring, and pointed out the direction of future work for entrepreneurs. 2020 08-05 |